11.18.15
PlaqueTec, a Cambridge,UK-based company developing a biomarker-based approach to transform the understanding of coronary artery disease (CAD), the leading cause of death worldwide, has appointed Nick West as chief medical officer.
Dr. West is a consultant interventional cardiologist at Papworth Hospital, Cambridge, the UK’s largest specialist cardiothoracic unit. He has worked with PlaqueTec for a number of years as medical advisor, and was principal investigator for both PlaqueTec’s recent clinical study and the first-in-man study that preceded it.
“We are delighted that Nick has joined us as CMO,” said Tim Brears, chief executive officer, PlaqueTec. “He has significant experience in interventional cardiology and was integral to the development of PlaqueTec’s Liquid Biopsy System. He is an important addition to our team and will play a key role in the future development of our company.”
Dr. West is a consultant interventional cardiologist at Papworth Hospital, Cambridge, the UK’s largest specialist cardiothoracic unit. He has worked with PlaqueTec for a number of years as medical advisor, and was principal investigator for both PlaqueTec’s recent clinical study and the first-in-man study that preceded it.
“We are delighted that Nick has joined us as CMO,” said Tim Brears, chief executive officer, PlaqueTec. “He has significant experience in interventional cardiology and was integral to the development of PlaqueTec’s Liquid Biopsy System. He is an important addition to our team and will play a key role in the future development of our company.”
